London, May 10th 2016 - Bryan Garnier, the independent European investment bank partnership, is pleased to announce the arrival of Dr Brigitte de Lima, Director of the healthcare sector. Dr de Lima is joining Bryan Garnier’s London office where she will be responsible for the firm’s healthcare practice in the UK, working closely with Bryan Garnier’s international healthcare team. A highly qualified finance professional with over ten years of healthcare/life sciences experience and strong scientific background, Dr de Lima has advised and worked with leading global pharma and biotech companies, such as Sanofi, Acambis, Actelion, bioMérieux, DiaSorin, Genmab, Lonza, Lundbeck, Merck, Qiagen and UCB. Her PhD in Virology/Molecular Biology and her ability to work in English, German, Spanish and Portuguese make her an ideal partner to fast growing healthcare companies looking to realise international growth. Prior to working as a corporate finance adviser to healthcare companies, Dr de Lima was a highly rated biotechnology equity researcher at Bank of America Merrill Lynch, London.
Olivier Garnier, founding partner Bryan Garnier, commented: “Bryan Garnier continues to strengthen its position as the preeminent European healthcare investment bank. We are delighted to welcome Brigitte to our team of leading experts and bankers in this exciting growth sector. Brigitte’s academic excellence and deep understanding of this complex industry and her strong banking credentials make her an ideal addition to our UK team.”
Brigitte de Lima added: “Bryan Garnier has consistently been at the forefront of advising outstanding biotech, pharma and healthcare companies, as well as financing publically or privately their growth. I am delighted to join this strong platform and to contribute to its growth in a key international market”.
Brigitte holds a PhD in Virology from Cambridge University and obtained a first class degree in Biochemistry from the University of Lisbon. She has been a CFA Charterholder since 2009.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an independent investment bank specialized in European growth companies, providing them with Equity Research & Brokerage, Asset Management and Corporate Finance services. With more than 150 professionals throughout London, Paris, Munich, New York, Geneva and New Delhi, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique. Bryan, Garnier & Co is a leading advisor to European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital markets, LBOs and private placements. Bryan, Garnier & Co is authorized and regulated by the Financial Conduct Authority (FCA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.
In 2015, Bryan, Garnier & Co completed more than 35 transactions on European growth companies, including landmark transactions such as the acquisition of Metrologic from Carlyle, the sale of Codenomicon to Synopsis, the sale of cybersecurity Lexsi to Orange, the €25m private placement for Jahia, the IPOs of Bone Therapeutics or Amoeba on Euronext or Celyad and Galapagos on the Nasdaq.
In 2014 and 2015, Bryan, Garnier & Co was the most active investment bank involved in the IPO of European growth companies on the US Nasdaq. In December 2015, Bryan Garnier completed the acquisition of Cartagena Capital in Germany.